The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in adults aged older than 75 years.
 
Yuta Yamanaka
No Relationships to Disclose
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; Pfizer
Research Funding - Amgen; AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Kageaki Watanabe
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly O.; Merck; MSD; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly O.; Merck; MSD; Ono Pharmaceutical; Takeda
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin International; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hidehito Horinouchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); BMKK (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yoshiro Nakahara
Honoraria - AstraZeneca; BMSi; Boehringer Ingelheim; Chugai Pharma; Lilly O.; Nippon Kayaku; Ono Pharmaceutical; Taiho Oncology; Takeda
Research Funding - AstraZeneca; BMSi; Boehringer Ingelheim; Chugai Pharma; Lilly O.; Nippon Kayaku; Ono Pharmaceutical; Taiho Oncology; Takeda
 
Tetsuhiko Asao
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Nippon Boehringer Ingelheim
 
Sho Saeki
No Relationships to Disclose
 
Yukari Tsubata
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst)
 
Yu Fujita
Honoraria - AstraZeneca; MSD
Research Funding - AstraZeneca; MSD
 
Jun Sakakibara-Konishi
No Relationships to Disclose
 
Hidenori Mizugaki
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
 
Mayu Ouchi
No Relationships to Disclose
 
Shigehiro Yagishita
Speakers' Bureau - LSI Medience Corporation
Patents, Royalties, Other Intellectual Property - glycosylation analysis of antibody drugs
 
Akinobu Hamada
Research Funding - Boehringer Ingelheim; Chordia Therapeutics; Chugai Pharma; CMIC Pharma Science; Eisai; Healios; Konica Minolta; Lilly; LSI Medience Corporation; Sysmex; Tosoh Corporation